Smartest Doc
Comparison of Lafutidine and Rabeprazole in 7-day Second-line Amoxicillin- and Metronidazole-Containing Triple Therapy for Helicobacter pylori: A Pilot Study
Helicobacter, 04/05/2012
Clinical Article
Kudo T et al. – Lafutidine plus metronidazole–amoxicillin as second–line therapy provided a high eradication rate and safe treatment similar to a PPI–based regimen. Lafutidine–based eradication therapy is therefore considered to be a promising alternative and is also expected to reduce health care costs in H. pylori eradication.
Methods- Fifty-two patients who failed in first-line eradication using PPI–amoxicillin-clarithromycin were randomly assigned to a 7-day course of rabeprazole at 10 mg b.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (RPZ-AM) or a 7-day course of lafutidine at 10 mg t.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (LFT-AM) as second-line therapy.
- Eradication was assessed by the 13C urea breath test.
- A drug susceptibility test was performed before the second-line therapy.
- Prior to second-line H. pylori eradication, the rate of resistance to clarithromycin was 86.5% and the rate of resistance to metronidazole was 3.8%.
- The eradication rates for both LFT-AM and RPZ-AM groups were 96% (95%CI = 88.6–100%).
- There were no severe adverse events in either group.
